Team Identifies Key Driver Of Cancer Cell Death Pathway That Activates Immune Cells
CHAMPAIGN — Scientists have identified a protein that plays a pivotal role in the action of several emerging cancer therapies. The researchers say the discovery will likely aid efforts to fine-tune the use of immunotherapies against several challenging cancers. They report their findings in the journal Cancer Research. “Most anticancer drugs cause cancer cells to shrivel up and die in a controlled process known as apoptosis. But apoptosis does not usually strongly activate immune cells,” said David Shapiro, a professor of biochemistry at the University of Illinois Urbana-Champaign who led the research with former graduate student Santanu Ghosh. “However, a few emerging cancer therapies cause cancer cells to swell up and burst. The protein we identified, a sodium-ion channel known as TRPM4, is critical for cancer therapies that promote this type of cell death, called necrosis.” Unlike apoptosis, necrosis strongly signals the immune system to target and
stLouIST